CME Webcast Teaches on Preventive Cardiology

OSUWexnerbloglogo2014 CME Webcast Teaches on Preventive Cardiology. The best way to improve outcomes in cardiovascular disease is to not get it in the first place and today on MedNet21, we are going to show you what you can do to prevent heart disease in your patients. Let me welcome today’s guests. Dr. Wesley Milks is a cardiologist and Assistant Professor of Internal Medicine and Kelly Bartsch is a pharmacist specializing in lipid management.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: REVIEW
the mechanisms of action of the major medication classes utilized in the 2018 multi-society cholesterol guidelines; and UNDERSTAND the influence of the new cardiovascular outcomes trials for ezetimibe and the PCSK9 inhibitors on the new cholesterol guidelines; DEMONSTRATE understanding of key atherosclerotic risk and risk-enhancing factors as well as of recent pivotal lipid lowering treatment guidelines; and SELECT the appropriate target of lipid lowering therapy (e.g. LDL-C or non-HDL-C) with respect to the patient’s comorbid metabolic conditions.

You’ll also learn about the following:

  • Cholesterol level goals
  • Indications for medical treatment of lipids
  • Follow-up of patients started on cholesterol lowering drugs
  • Monitoring of cholesterol lowering drugs
  • CRP and other inflammatory markers

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Fertility Preservation in the Adolescent and Young Adult Population

OSUWexnerbloglogo2014 Fertility Preservation in the Adolescent and Young Adult Population will be discussed on this CME webcast. We are going to show you just how far medical science has come in order to preserve fertility in girls and young women. Joining our moderator in the studio is Associate Professor of Obstetrics and Gynecology, Dr. Leslie Appiah.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: EXPLAIN the effects of cancer treatments on fertility and limits of risk stratification; DISCUSS standard and novel fertility preservation therapies for patients with cancer; and DESCRIBE reproductive late effects and management options in survivorship.

You’ll also learn about the following:

  • Common indications for fertility preservation
  • Fertility preservation options
  • How long can tissues safely be frozen
  • How many eggs should be frozen
  • Options for pre-pubescent girls
  • Options for women undergoing oophorectomy
  • Fertility preservation for men

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcast Teaches on Immunosuppressant Medications

OSUWexnerbloglogo2014 CME Webcast Teaches on Immunosuppressant Medications. More and more, primary care physicians and hospitalists are finding themselves taking care of patients who have been started on immunosuppressant medication a transplant physician, rheumatologist, nephrologist, or pulmonologist. On this CME webcast, we’re going to tell you what you need to know about these medications, their side effects, and their complications. Let me introduce our guests. Dr. Brian Keller is a lung transplant pulmonologist and Assistant Professor Internal Medicine at The Ohio State University. And Pamela Burcham is a lung transplant specialty pharmacist from the OSU Wexner Medical Center.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS indications for immunosuppressive therapies; and DESCRIBE prophylaxis immunization, and pregnancy considerations for patients on Immunosuppressive therapy; UNDERSTAND the indications for individual immunosuppressants; and DESCRIBE the common adverse effects and monitoring parameters of the immunosuppressive medications.

You’ll also learn about the following:

  • Common indications for immunosuppressant medications
  • Commonly used immunosuppressant medications
  • Food safety for patients taking immunosuppressant medications
  • Pneumocystis jiroveci clinical presentation
  • Indications for TNF inhibitors
  • Infection risk of TNF inhibitors
  • Management of immunosuppressants in the perioperative period
  • Travel safety when taking an immunosuppressant
  • Bone health and corticosteroids
  • Eye health and corticosteroids
  • Monitoring for methotrexate-induced hepatotoxicity
  • Thiopurine methylytransferase
  • Cyclophosphamide

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Webcast Teaches on Anticoagulation and New Anticoagulants

OSUWexnerbloglogo2014 Webcast Teaches on Anticoagulation and New Anticoagulants. Now, we have even more anticoagulants and with all of the choices comes a lot of confusion. On this CME webcast, joining our moderator, to demystify all of the new anticoagulants and to give us some direction of when to choose one versus another is hematologist and Assistant Professor of Internal Medicine from the Ohio State University, Dr. Tzu-Fei Wang.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: State the differences of old anticoagulation and new direct oral anticoagulants and know the four approved direct oral anticoagulant; and UNDERSTAND the indications, laboratory testing, and precautions when prescribing direct oral anticoagulants.

You’ll also learn about the following:

  • The problem with Coumadin
  • Currently available direct oral anticoagulants
  • When Coumadin is the best option
  • Mitigating malpractice risk when prescribing direct oral anticoagulants

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.